<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2019.81013</article-id><article-id pub-id-type="publisher-id">TCM-28655</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20190100000_30278191.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  姜黄素与非酒精性脂肪肝疾病
  Curcumin and Nonalcoholic Fatty Liver Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>廖</surname><given-names>梦君</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>喻</surname><given-names>翠云</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>阳</surname><given-names>学风</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>南华大学药学院药物药理研究所，湖南 衡阳</addr-line></aff><aff id="aff1"><addr-line>南华大学附属南华医院麻醉科，湖南 衡阳</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>12</month><year>2018</year></pub-date><volume>08</volume><issue>01</issue><fpage>61</fpage><lpage>67</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   非酒精性脂肪性肝病(non alcohol fatty liver disease, NAFLD)是全球最常见的慢性肝病，NAFLD在不同人群中的患病率在25%~45%之间，由于全球肥胖症和糖尿病患病率的增加，NAFLD呈上升趋势。NAFLD的范围从临床上最良性的肝脂肪变性，到非酒精性脂肪肝(NASH) (一种中间病变)，再到肝硬化甚至肝功能衰竭和死亡。姜黄素(curcumin)是姜黄(Curcuma longa L.)是姜黄中具有生物活性的多酚类色素。近几十年来，越来越多的研究表明姜黄素在肝脏疾病的治疗中起着重要作用，已成为人们越来越感兴趣的研究对象，它通过多种细胞和分子机制对非酒精性脂肪肝疾病具有显著的保护和治疗作用。本文主要针对姜黄素治疗非酒精性脂肪肝进行综述。 Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world; the prevalence of NAFLD in different populations is 25% - 45%; due to the global increase in obesity and diabetes prevalence, NAFLD is on the rise. NAFLD ranges from clinically benign hepatic steatosis to non-alcoholic fatty liver disease (NASH), an intermediate disease, to cirrhosis and even liver failure and death. Considering the high prevalence of NAFLD and its adverse impact on patients’ quality of life, curcumin is Curcuma longa L., a bioactive polyphenol pigment in turmeric. In recent decades, more and more studies have shown that curcumin plays an important role in the treatment of liver diseases and has become an increasingly interesting research object. It has significant protective and therapeutic effects on non-alcoholic fatty liver diseases through a variety of cellular and molecular mechanisms. This article mainly reviews curcumin treatment of nonalcoholic fatty liver disease. 
  
 
</p></abstract><kwd-group><kwd>姜黄素，非酒精性脂肪肝，脂质，氧化应激，炎症，凋亡，自噬，肝星状细胞, Curcumin</kwd><kwd> Nonalcoholic Fatty Liver</kwd><kwd> Lipid</kwd><kwd> Oxidative Stress</kwd><kwd> Inflammation</kwd><kwd> Apoptosis</kwd><kwd> Autophagy</kwd><kwd> Hepatic Stellate Cell</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>姜黄素与非酒精性脂肪肝疾病<sup> </sup></title><p>廖梦君<sup>1</sup>，喻翠云<sup>2*</sup>，阳学风<sup>1</sup></p><p><sup>1</sup>南华大学附属南华医院麻醉科，湖南 衡阳</p><p><sup>2</sup>南华大学药学院药物药理研究所，湖南 衡阳</p><disp-formula id="hanspub.28655-formula34"><graphic xlink:href="//html.hanspub.org/file/13-2270391x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年1月5日；录用日期：2019年1月21日；发布日期：2019年1月28日</p><disp-formula id="hanspub.28655-formula35"><graphic xlink:href="//html.hanspub.org/file/13-2270391x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>非酒精性脂肪性肝病(non alcohol fatty liver disease, NAFLD)是全球最常见的慢性肝病，NAFLD在不同人群中的患病率在25%~45%之间，由于全球肥胖症和糖尿病患病率的增加，NAFLD呈上升趋势。NAFLD的范围从临床上最良性的肝脂肪变性，到非酒精性脂肪肝(NASH) (一种中间病变)，再到肝硬化甚至肝功能衰竭和死亡。姜黄素(curcumin)是姜黄(Curcuma longa L.)是姜黄中具有生物活性的多酚类色素。近几十年来，越来越多的研究表明姜黄素在肝脏疾病的治疗中起着重要作用，已成为人们越来越感兴趣的研究对象，它通过多种细胞和分子机制对非酒精性脂肪肝疾病具有显著的保护和治疗作用。本文主要针对姜黄素治疗非酒精性脂肪肝进行综述。</p><p>关键词 :姜黄素，非酒精性脂肪肝，脂质，氧化应激，炎症，凋亡，自噬，肝星状细胞</p><disp-formula id="hanspub.28655-formula36"><graphic xlink:href="//html.hanspub.org/file/13-2270391x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-2270391x8_hanspub.png" /> <img src="//html.hanspub.org/file/13-2270391x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>姜黄素[1,7-双(4-羟基-3-甲氧基苯基)-1,6-庚二烯3,5-二酮]是从姜黄根中提取的一种天然黄色多酚。姜黄根是一种生长在世界热带和亚热带地区的植物，在许多亚洲国家广泛用于食品制备。姜黄素具有抗炎、抗氧化、抗病毒和清除氧自由基、降低血脂、保护肾脏、预防癌症和抗癌等作用 [<xref ref-type="bibr" rid="hanspub.28655-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref4">4</xref>] 。姜黄素的使用在许多国家的传统医学中已经有数百年的历史。近年来发现，姜黄素在治疗肝脏疾病方面表现出了非常好的前景 [<xref ref-type="bibr" rid="hanspub.28655-ref5">5</xref>] 。考虑到NAFLD的高患病率和对患者生活质量的不利影响，本文主要目的是总结姜黄素在治疗非酒精性脂肪肝脏疾病中的作用，并着重针对姜黄素治疗非酒精性脂肪肝的药物作用及机制进行综述。</p></sec><sec id="s4"><title>2. 姜黄素对非酒精性脂肪肝病的作用机制</title><p>非酒精性脂肪肝的标志是由于酒精滥用以外的其他因素导致的肝脏脂肪堆积。胰岛素抵抗已被认为是NAFLD [<xref ref-type="bibr" rid="hanspub.28655-ref6">6</xref>] 及其相关共病(包括中央型肥胖、2型糖尿病和代谢综合征)发病机制的关键触发因素。NAFLD的治疗主要取决于其严重程度，无论是否治疗，NAFLD在特定人群中都可能发展为纤维化和肝硬化，并且随着年龄的增长、糖尿病和肥胖症的增加，其风险也会增加 [<xref ref-type="bibr" rid="hanspub.28655-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref9">9</xref>] 。因此，寻找有效、安全控制NAFLD/NASH的治疗药物具有重要意义。目前，通过临床研究及特殊动物模型研究，对NAFLD发病机制的认识取得一定的进展 [<xref ref-type="bibr" rid="hanspub.28655-ref10">10</xref>] 。最被接受的理论是Day和James [<xref ref-type="bibr" rid="hanspub.28655-ref5">5</xref>] 提出的“双击假说”。“第一个打击”是脂肪变性的发展，长期营养过剩导致脂质代谢失调，并在肝脏中引发游离脂肪酸(FFAs)和甘油三酯的积累。在“第二次打击”中，脂肪变性由于氧化应激、线粒体功能障碍和炎症细胞因子而发展为炎症和纤维化，导致肝细胞炎症和坏死，激活肝细胞纤维化。姜黄素可以改善胰岛素抵抗和高甘油三酯血症，姜黄素还可以通过对抗氧化应激及炎性反应，降低肝细胞凋亡水平，诱导变性肝细胞自噬，阻止HSC活化和促进HSC调亡，影响ECM的合成和代谢起到治疗非酒精脂肪性肝病的作用 [<xref ref-type="bibr" rid="hanspub.28655-ref11">11</xref>] 。</p><sec id="s4_1"><title>2.1. 抗脂质</title><p>肝细胞中脂质的异常积累(5%或更高)通常被称为脂肪变性。大泡脂肪变性形成为非酒精性脂肪性肝炎(NASH)病灶发展的有利环境。姜黄素已被证明可以减少高脂饮食啮齿类动物肝细胞内的脂质储存，有助于减少线粒体功能障碍和氧化应激引起的肝脏损伤。Rao等 [<xref ref-type="bibr" rid="hanspub.28655-ref12">12</xref>] 报道了姜黄素的降血脂活性的初步数据，结果显示，与只喂食胆固醇的大鼠相比，同时喂食胆固醇和姜黄素的大鼠肝脏胆固醇含量较低。随后，Asai和Miyazawa [<xref ref-type="bibr" rid="hanspub.28655-ref13">13</xref>] 研究表明，补充1.0 g姜黄素/100 g饲料的雄性Sprague-Dawley大鼠与未补充姜黄素的对照组大鼠相比，其肝脏三酰基甘油和胆固醇浓度显著降低。这可以解释姜黄素在体内具有降血脂作用。Rukkumani等 [<xref ref-type="bibr" rid="hanspub.28655-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref15">15</xref>] 评估了姜黄素及其合成类似物在酒精诱导和高脂肪饮食肝损伤雄性大鼠模型中的肝保护和降血脂的作用。在这两个实验中，姜黄素被证明可以减轻肝脏的组织病理学变化，并降低肝脏组织中胆固醇、甘油三酯的水平。最近，Jang等人 [<xref ref-type="bibr" rid="hanspub.28655-ref16">16</xref>] 研究表明，在仓鼠高脂饮食中补充姜黄素可以降低循环脂质的水平和肝脏脂质的水平。姜黄素也已被证明能够显著抑制关键蛋白质的表达和活动参与新陈代谢，如肝蛋白酪氨酸磷酸酶1 B (PTP1B)，姜黄素还能够降低LOX-1的表达，阻断细胞外OX-LDL进入造血干细胞，从而阻止其活化 [<xref ref-type="bibr" rid="hanspub.28655-ref17">17</xref>] 。很明显，姜黄素具有降血脂作用，可阻止脂肪酸在肝细胞中积累，这是各种代谢失衡导致最终导致NASH的结果。尽管姜黄素在动物模型中的抗脂质作用有积极的研究结果，但在临床实践中探讨姜黄素抗脂质作用的研究较少 [<xref ref-type="bibr" rid="hanspub.28655-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref20">20</xref>] 。</p></sec><sec id="s4_2"><title>2.2. 降低氧化应激</title><p>氧化应激是脂肪肝第二次打击的重要原因，它在脂肪肝的形成和发展过程中起着非常重要的作用。而非酒精性肝硬化往往伴随着氧化应激的增加。活性氧(ros)对组织具有很强的破坏性，是由分子氧在氧化过程中形成的中间产物，并且Ros可以通过氧化大分子引起损伤 [<xref ref-type="bibr" rid="hanspub.28655-ref21">21</xref>] 。活性氧(ROS)水平过高，活性氧的产生和降解不平衡可导致蛋白质、脂质降解。活性氧(ROS)还参与肝纤维化发生，并参与缺血、再生、坏死和凋亡的过程。氧化应激还可加重胰岛素抵抗，激活多种炎性细胞因子，损伤细胞核DNA并诱导细胞凋亡的发生，被认为是NAFLD由单纯脂肪变性向NASH发展的最关键环节 [<xref ref-type="bibr" rid="hanspub.28655-ref22">22</xref>] 。SOD是重要抗氧化酶，它可以清除机体自由基；T-AOC可代表生物体内抗氧化剂的总体水平；GSH-Px能催化过氧化物还原生成无毒羟基化合物，保护细胞不受过氧化物的损害 [<xref ref-type="bibr" rid="hanspub.28655-ref22">22</xref>] ；MAD是自由基与脂质过氧化反应的最终产物。它们都是衡量细胞氧化应激水平的重要指标 [<xref ref-type="bibr" rid="hanspub.28655-ref23">23</xref>] 。姜黄素具有抗氧化活性，通过影响氧化应激的多个过程和信号传导通路有效清除肝细胞内过多的活性氧自由基，调节体内氧化应激酶的活性。有研究发现，高脂饮食大鼠通过姜黄素干预后，血清中SOD、T-AOC、GSH-Px均有明显的升高，MAD降低，表明姜黄素能增强非酒精性脂肪肝大鼠肝脏抗氧化活性，抑制自由基生成，降低氧化应激水平 [<xref ref-type="bibr" rid="hanspub.28655-ref24">24</xref>] 。姜黄素还可以通过干扰HSC上胰岛素信号通路，诱导胱氨酸连接酶的表达合成谷胱甘肽，减轻了胰岛素诱导的肝脏的氧化应激 [<xref ref-type="bibr" rid="hanspub.28655-ref25">25</xref>] 。</p></sec><sec id="s4_3"><title>2.3. 减少炎症反应</title><p>在肝脏中，NF-κB可以调节多种炎症因子的表达。激活后，通过增加TNF-α、IL-6、IL-1等炎症因子的表达水平，参与肝脏的炎症反应过程。是NAFLD发展的重要机制 [<xref ref-type="bibr" rid="hanspub.28655-ref26">26</xref>] 。研究发现，NAFLD大鼠TNF-α和IL-6的表达明显高于正常对照组，在炎症细胞中诱导炎症反应，加重肝细胞损伤 [<xref ref-type="bibr" rid="hanspub.28655-ref27">27</xref>] 。大量体外研究表明姜黄素具有强大的抗氧化和抗炎作用，这可能是其在慢性肝病中的保护作用的原因。姜黄素能下调非酒精性脂肪肝细胞中的多种炎症相关信号通路活性和基因转录，抑制趋化因子和炎症介质的释放，减少炎症细胞的增殖和活化。AFRIN等 [<xref ref-type="bibr" rid="hanspub.28655-ref28">28</xref>] 研究发现，姜黄素降低NASH小鼠IFNβ-γ和IL-1β诱导蛋白等促炎因子的表达，并且HMGB1、NF-κB的转录表达也明显下降，说明姜黄素通过抑制HMGB1，NF-κB的转录，延缓NASH进程。</p></sec><sec id="s4_4"><title>2.4. 抑制细胞凋亡</title><p>细胞凋亡被认为是程序化细胞的一种形式死亡和各种过程的主要组成部分，如平衡细胞再生和消除，免疫功能系统等等。诱导细胞凋亡后，细胞出现皱缩，DNA损伤，染色质凝聚，膜起泡，以及体内凋亡小体的碎裂和发育核等形态变化。NAFLD肝脏中的饱和脂肪酸和游离胆固醇等诱导肝细胞凋亡。PCNA、caspase-3、caspase-8、caspase-9、Bax和Bcl-2基因是细胞增殖和凋亡相关途径的关键因子，凋亡水平由 Bcl-2和Bax蛋白表达水平的比值决定 [<xref ref-type="bibr" rid="hanspub.28655-ref29">29</xref>] 。实验表明，姜黄素治疗后肝组织中的Bcl-2表达水平增高而 Bax表达水平降低，说明姜黄素通过激活Bcl-2并抑制Bax表达，增加Bcl-2/Bax比值抑制NAFLD大鼠肝细胞凋亡 [<xref ref-type="bibr" rid="hanspub.28655-ref24">24</xref>] 。Li [<xref ref-type="bibr" rid="hanspub.28655-ref30">30</xref>] 等同时证实姜黄素可上调对乙酰氨基酚(APAP)所致小鼠急性肝损伤模型中凋亡相关基因Bcl-2/Bax的比值。降低肝细胞凋亡水平。因此，姜黄素能显著改善NAFLD肝细胞凋亡。</p></sec><sec id="s4_5"><title>2.5. 促进肝细胞自噬</title><p>自噬是一种细胞过程，通过吞噬多余的细胞器和蛋白质，在细胞质中形成双膜自噬体，然后与溶酶体结合以进行降解。正常水平的自噬是对维持正常的肝脏功能有着非常重要的作用。然而，过度的自噬会破坏正常蛋白质和细胞器 [<xref ref-type="bibr" rid="hanspub.28655-ref31">31</xref>] 。因此，自噬能促进细胞存活，也能导致细胞死亡。在NAFLD中，通过清除损伤的细胞器或累积的多余的蛋白质聚集物等来维持细胞内环境的稳态从而降低对细胞的损伤的过程称为自噬。研究表明，高脂饮食小鼠肝组织自噬活性增加，而通过自噬抑制剂抑制肝细胞自噬后反而促进了细胞凋亡。说明在脂肪酸诱导的肝细胞损伤过程中，自噬对肝细胞起保护作用 [<xref ref-type="bibr" rid="hanspub.28655-ref32">32</xref>] - [<xref ref-type="bibr" rid="hanspub.28655-ref44">44</xref>] 。还有研究证实，姜黄素能诱导肝癌、乳腺癌、结肠癌和肺癌等肿瘤细胞的自噬 [<xref ref-type="bibr" rid="hanspub.28655-ref42">42</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref43">43</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref44">44</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref45">45</xref>] 。近年来的研究已阐明串扰凋亡与自噬的关系。有一些相交的蛋白质调节细胞凋亡和自噬，如结果研究已确定抗凋亡蛋白bcl-2和促凋亡蛋白Bim为相互作用伙伴。另外，自噬也受许多其他信号的调节，例如哺乳动物的目标雷帕霉素(mTOR)和AMP活化蛋白激酶(AMPK)作出回应营养素，生长因子和能量压力。据报道，姜黄素似乎激活了许多细胞过程JNK1和AMPK信号通路，进而调节各种细胞凋亡和自噬细胞。目前，姜黄素诱导非酒精性脂肪性肝病细胞自噬机理仍需进一步研究。</p></sec><sec id="s4_6"><title>2.6. 阻止肝星状细胞活化</title><p>非酒精性脂肪性肝炎(NASH)是一种晚期非酒精性脂肪性肝病，通常与肥胖和/2型糖尿病有关。大约三分之一的NASH中存在肝纤维化。肝纤维化可进一步发展为肝硬化甚至肝细胞癌，导致肝衰竭、门脉高压甚至死亡。肝星状细胞(hepatic Stellate cells, HSC)激活是肝纤维化发展过程中的关键环节。因此，有效抑制HSC的活化，促进HSC的凋亡清除，从而减少以胶原纤维为主的细胞外基质的沉积，对逆转肝纤维化在非酒精性疾病治疗中具有重要意义。近年来，多项研究发现，姜黄素在抑制HSC激活，促进HSC凋亡清除方面有重要作用。研究证实姜黄素可以抑制HSC的活化和增殖，在G2/M期抑制细胞周期，诱导HSC凋亡，并具有剂量–时间依赖性 [<xref ref-type="bibr" rid="hanspub.28655-ref46">46</xref>] 。Lin等 [<xref ref-type="bibr" rid="hanspub.28655-ref47">47</xref>] 以大鼠HSC-T6细胞系为研究对象，发现姜黄素在TGF-β刺激后抑制HSC-T6细胞中SMA的表达和胶原沉积，说明其具有抗纤维化作用。然而，姜黄素浓度的增加引起了不同的效应，因为它们诱导了HSC-T6细胞凋亡。因此，姜黄素在这一水平上通过不同的剂量依赖机制发挥其肝保护作用。抑制HSC活化、增殖，可以从细胞因子及其信号转导途径进行调控，也可以通过清除肝细胞及内皮细胞损伤坏死时释放的氧化刺激因子，如氧自由基和炎性细胞因子等环节来进行。姜黄素通过下调PDGF-βR，EGFR和TGF-β并且诱导PPAR-γmRNA水平抑制HSC的活化和增殖，导致细胞外基质胶原蛋白的产生减少，保护肝脏不发生纤维化 [<xref ref-type="bibr" rid="hanspub.28655-ref48">48</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref49">49</xref>] 。研究发现，姜黄素可以干扰胰岛素受体IRS-PI3k-AKT信号通路，抑制GLUT4膜转位从而抑制HSC活化 [<xref ref-type="bibr" rid="hanspub.28655-ref50">50</xref>] [<xref ref-type="bibr" rid="hanspub.28655-ref51">51</xref>] 。自然杀伤细胞(NK细胞)在HSC的清除中也起着重要作用。KINGER等 [<xref ref-type="bibr" rid="hanspub.28655-ref52">52</xref>] 发现，姜黄素可以促进HSC衰老，改善主要组织相容性复合体I相关基因A和NK细胞活性，例如，UL16连接蛋白配体表达对NK细胞中HSC的老化敏感，并促进HSC老化的清除。</p></sec></sec><sec id="s5"><title>3. 小结</title><p>综上所述，姜黄素通过以上多种作用机制起到治疗非酒精性脂肪肝病作用，它可能成为预防和治疗非酒精性脂肪肝的有效药物。然而其确切机制仍需进一步探索。但目前姜黄素在调控脂变肝细胞的作用机制报道甚少。因此，今后应进一步扩大从脂变细胞自噬这一视角明确姜黄素保护肝细胞的作用机制，为非酒精性脂肪性肝病防治寻找新的治疗靶点。</p></sec><sec id="s6"><title>文章引用</title><p>廖梦君,喻翠云,阳学风. 姜黄素与非酒精性脂肪肝疾病Curcumin and Nonalcoholic Fatty Liver Disease[J]. 中医学, 2019, 08(01): 61-67. https://doi.org/10.12677/TCM.2019.81013</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28655-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, M.M., Khan, M.A. and Rainsford, K.D. (2013) Synthesis of Thiophene and NO-Curcuminoids for Antiin-flammatory and Anti-Cancer Activities. Molecules, 18, 1483-501.</mixed-citation></ref><ref id="hanspub.28655-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Jantan, I., Saputri, F.C., Qaisar, M.N. and Buang, F. (2012) Correlation between Chemical Composition of Curcuma domestica and Curcuma xanthorrhiza and Their Antioxidant Effect on Human Low-Density Lipoprotein Oxidation. Evidence-Based Complementary and Alternative Medicine, 2012, 438356.</mixed-citation></ref><ref id="hanspub.28655-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.L., Sun, Y., Huang, K. and Zheng, L. (2013) Curcumin, a Potential Therapeutic Candidate for Retinal Diseases. Molecular Nutrition &amp; Food Research. &lt;br&gt;https://doi.org/10.1002/mnfr.201200718</mixed-citation></ref><ref id="hanspub.28655-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tokaç, M., Taner, G., Aydın, S., Ozkardeş, A.B., Dündar, H.Z., Taşlıpınar, M.Y., Arıkök, A.T., Kılıç, M., Başaran, A.A. and Basaran, N. (2013) Protective Effects of Curcumin against Oxidative Stress Parameters and DNA Damage in the Livers and Kidneys of Rats with Biliary Obstruction. Food and Chemical Toxicology, 29, 00053-7.  
&lt;br&gt;https://doi.org/10.1016/j.fct.2013.01.015</mixed-citation></ref><ref id="hanspub.28655-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Vera-Ramirez, L., Pérez-Lopez, P., Varela-Lopez, A., Rami-rez-Tortosa, M., Battino, M. and Quiles, J.L. (2013) Curcumin and Liver Disease. Biofactors, 39, 88-100. &lt;br&gt;https://doi.org/10.1002/biof.1057</mixed-citation></ref><ref id="hanspub.28655-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cecil, R.L.F., Goldman, L. and Schafer, A.I. (2012) Goldman’s Cecil Medicine, Expert Consult Premium Edition-Enhanced Online Features and Print. Goldman’s Cecil Medicine, Elsevier/Saunders.</mixed-citation></ref><ref id="hanspub.28655-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bellentani, S., Saccoccio, G., Masutti, F., Crocè, L.S., Brandi, G., Sasso, F., Cristanini, G. and Tiribelli, C. (2000) Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. Annals of Internal Medicine, 132, 112-117.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-132-2-200001180-00004</mixed-citation></ref><ref id="hanspub.28655-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lonardo, A., Loria, P., Leonardi, F., Borsatti, A., Neri, P., Pulvirenti, M., Verrone, A.M., Bagni, A., Bertolotti, M., Ganazzi, D., et al. (2002) Fasting Insulin and Uric Acid Levels but Not Indices of Iron Metabolism Are Independent Predictors of Non-Alcoholic Fatty Liver Disease. A Case-Control Study. Digestive and Liver Disease, 34, 204-211.  
&lt;br&gt;https://doi.org/10.1016/S1590-8658(02)80194-3</mixed-citation></ref><ref id="hanspub.28655-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Omagari, K., Kadokawa, Y., Masuda, J., Egawa, I., Sawa, T., Hazama, H., Ohba, K., Isomoto, H., Mizuta, Y., Hayashida, K., et al. (2002) Fatty Liver in Non-Alcoholic Non-Overweight Japanese Adults: Incidence and Clinical Characteristics. Journal of Gastroenterology and Hepatology, 17, 1098-1105.  
&lt;br&gt;https://doi.org/10.1046/j.1440-1746.2002.02846.x</mixed-citation></ref><ref id="hanspub.28655-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Anstee, Q.M. and Goldin, R.D. (2006) Mouse Models in Non-Alcoholic Fatty Liver Disease and Steatohepatitis Research. International Journal of Experimental Pathology, 87, 1-16. &lt;br&gt;https://doi.org/10.1111/j.0959-9673.2006.00465.x</mixed-citation></ref><ref id="hanspub.28655-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">孙永, 彭明利. 姜黄素及其衍生物在肝脏相关疾病中防治作用的研究进展[J]. 药学学报, 2014, 49(11): 1483-1490.</mixed-citation></ref><ref id="hanspub.28655-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Rao, D.S., Sekhara, N.C., Satyanarayana, M.N. and Srinivasan, M. (1970) Effect of Curcumin on Serum and Liver Cholesterol Levels in the Rat. The Journal of Nutrition, 100, 1307-1315. &lt;br&gt;https://doi.org/10.1093/jn/100.11.1307</mixed-citation></ref><ref id="hanspub.28655-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Asai, A. and Miyazawa, T. (2001) Dietary Curcuminoids Prevent High-Fat Diet-Induced Lipid Accumulation in Rat Liver and Epididymal Adipose Tissue. The Journal of Nutrition, 131, 2932-2935.  
&lt;br&gt;https://doi.org/10.1093/jn/131.11.2932</mixed-citation></ref><ref id="hanspub.28655-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Rukkumani, R., Sri Balasubashini, M., Vishwanathan, P. and Menon, V.P. (2002) Comparative Effects of Curcumin and Photo-Irradiated Curcumin on Alcohol- and Polyunsaturated Fatty Acid-Induced Hyperlipidemia. Pharmacological Research, 46, 257-264. &lt;br&gt;https://doi.org/10.1016/S1043-6618(02)00149-4</mixed-citation></ref><ref id="hanspub.28655-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Rukkumani, R., Aruna, K., Varma, P.S., Viswanathan, P., Rajasekaran, K.N., et al. (2005) Protective Role of a Novel Curcuminoid on Alcohol and PUFA-Induced Hyperlipidemia. Toxicology Mechanisms and Methods, 15, 227-234.  
&lt;br&gt;https://doi.org/10.1080/15376520590945658</mixed-citation></ref><ref id="hanspub.28655-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jang, E.M., Choi, M.S., Jung, U.J., Kim, M.J., Kim, H.J., et al. (2008) Beneficial Effects of Curcumin on Hyperlipidemia and Insulin Resistance in High-Fat-Fed Hamsters. Metabolism, 57, 1576-1583.  
&lt;br&gt;https://doi.org/10.1016/j.metabol.2008.06.014</mixed-citation></ref><ref id="hanspub.28655-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kang, Q. and Chen, A. (2009) Curcumin Eliminates Oxidized LDL Roles in Activating Hepatic Stellate Cells by Suppressing Gene Expression of Lectinlike Oxidized LDL Receptor-1. Laboratory Investigation, 89, 1275-1290.  
&lt;br&gt;https://doi.org/10.1038/labinvest.2009.93</mixed-citation></ref><ref id="hanspub.28655-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simen-tal-Mendia, L.E. and Sahebkar, A. (2017) Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Research, 67, 244-251. &lt;br&gt;https://doi.org/10.1055/s-0043-100019</mixed-citation></ref><ref id="hanspub.28655-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A. and Sahebkar, A. (2016) Treatment of Non-Alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-Controlled Trial. Phytotherapy Research, 30, 1540-1548. &lt;br&gt;https://doi.org/10.1002/ptr.5659</mixed-citation></ref><ref id="hanspub.28655-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E. and Sahebkar, A. (2016) Curcumin Lowers Serum Lipids and Uric Acid in Subjects with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Journal of Cardiovascular Pharmacology, 68, 223-229. &lt;br&gt;https://doi.org/10.1097/FJC.0000000000000406</mixed-citation></ref><ref id="hanspub.28655-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Cichoz-Lach, H. and Michalak, A. (2014) Oxidative Stress as a Crucial Factor in Liver Diseases. World Journal of Gastroenterology, 20, 80-82. &lt;br&gt;https://doi.org/10.3748/wjg.v20.i25.8082</mixed-citation></ref><ref id="hanspub.28655-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Takaki, A., Kawai, D. and Yamamoto, K. (2013) Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 14, 20704-20728. &lt;br&gt;https://doi.org/10.3390/ijms141020704</mixed-citation></ref><ref id="hanspub.28655-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Gao, H.T., Xu, L.S., Li, D.F., et al. (2013) Effects of Glucagon-Like Peptide-1 on Liver Oxidative Stress, TNF-α and TGF-β1 in Rats with Non-Alcoholic Fatty Liver Disease. Journal of Southern Medical University, 33, 1661-1664.</mixed-citation></ref><ref id="hanspub.28655-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">舒泳翔, 吴鹏波, 柳健, 等. 姜黄素对实验性大鼠非酒精性脂肪肝病氧化应激、炎性因子及细胞凋亡水平的影响[J]. 医学研究杂志, 2016, 45(3): 126-130.</mixed-citation></ref><ref id="hanspub.28655-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lin, J., Zheng, S. and Chen, A. (2009) Curcumin Attenuates the Effects of Insulin on Stimulating Hepatic Stellate Cell Activation by Interrupting Insulin Signaling and Attenuating Oxidative Stress. Laboratory Investigation, 89, 1397-1409. &lt;br&gt;https://doi.org/10.1038/labinvest.2009.115</mixed-citation></ref><ref id="hanspub.28655-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Braunersreuther, V., Viviani, G.L., Mach, F., et al. (2012) Role of Cytokines and Chemokines in Non-Alcoholic Fatty. World Journal of Gastroenterology, 18, 727-735. &lt;br&gt;https://doi.org/10.3748/wjg.v18.i8.727</mixed-citation></ref><ref id="hanspub.28655-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Z., Wai, J.T., Jin, J.Y., et al. (2014) Signal Transductions and Nonalcoholic Fatty Liver: A Mini-Review. International Journal of Clinical and Experimental Medicine, 7, 1624-1631.</mixed-citation></ref><ref id="hanspub.28655-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Afrin, R., Arumugam, S., Rahman, A., et al. (2017) Curcumin Ameliorates Liver Damage and Progression of NASH in NASH-HCC Mouse Model Possibly by Modulating HMGB1-NF-κB Translocation. International Immunopharmacology, 44, 174-182. &lt;br&gt;https://doi.org/10.1016/j.intimp.2017.01.016</mixed-citation></ref><ref id="hanspub.28655-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Feng, M., Li, J., Wang, J., et al. (2014) High Glucose Increases LPS-Induced DC Apoptosis through Modulation of ERK1/2, AKT and Bax/Bcl-2. BMC Gastroenterology, 14, 1-8. &lt;br&gt;https://doi.org/10.1186/1471-230X-14-98</mixed-citation></ref><ref id="hanspub.28655-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Li, G., Chen, J.B., Wang, C., et al. (2013) Curcumin Protects against Acetaminophen-Induced Apoptosis in Hepatic Injury. World Journal of Gastroenterology, 19, 7440-7446. &lt;br&gt;https://doi.org/10.3748/wjg.v19.i42.7440</mixed-citation></ref><ref id="hanspub.28655-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Dash, S., Chava, S., Chandra, P.K., et al. (2016) Autophagy in Hepatocellular Carcinomas: From Pathophysiology to Therapeutic Response. Hepatic Medicine: Evidence and Research, 8, 9-20.</mixed-citation></ref><ref id="hanspub.28655-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Tan, T.C., Crawford, D.H., Jaskowski, L.A., Subramaniam, V.N., Clouston, A.D., Crane, D.I., Bridle, K.R., Anderson, G.J. and Fletcher, L.M. (2013) Excess Iron Modulates Endoplasmic Reticulum Stress-Associated Pathways in a Mouse Model of Alcohol and High-Fat Diet-Induced Liver Injury. Laboratory Investigation.  
&lt;br&gt;https://doi.org/10.1038/labinvest.2013.121</mixed-citation></ref><ref id="hanspub.28655-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Lake, A.D., Novak, P., Hardwick, R.N., Flores-Keown, B., Zhao, F., Klimecki, W.T. and Cherrington, N.J. (2013) The Adaptive Endoplasmic Reticulum Stress Response to Lipotoxicity in Progressive Human Nonalcoholic Fatty Liver Disease. Toxicological Sciences, 137, 26-35.</mixed-citation></ref><ref id="hanspub.28655-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Iancu, T.C., Manov, I., Shaoul, R., Haimi, M. and Lerner, A. (2013) What’s in a Name?—“Lipolysosome”: Ultrastructural Features of a Lipid-Containing Organelle. Ultrastructural Pathology, 37, 293-303.  
&lt;br&gt;https://doi.org/10.3109/01913123.2013.799625</mixed-citation></ref><ref id="hanspub.28655-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Li, L., Hai, J., Li, Z., Zhang, Y., Peng, H., Li, K. and Weng, X. (2013) Resveratrol Modulates Autophagy and NF-κB Activity in a Murine Model for Treating Non-Alcoholic Fatty Liver Disease. Food and Chemical Toxicology, 63, 166-173.</mixed-citation></ref><ref id="hanspub.28655-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Ma, D., Molusky, M.M., Song, J., Hu, C.R., Fang, F., Rui, C., Mathew, A.V., Pennathur, S., Liu, F., Cheng, J.X., Guan, J.L. and Lin, J.D. (2013) Autophagy Deficiency by Hepatic FIP200 Deletion Uncouples Steatosis from Liver Injury in NAFLD. Molecular Endocrinology, 27, 1643-1654. &lt;br&gt;https://doi.org/10.1210/me.2013-1153</mixed-citation></ref><ref id="hanspub.28655-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Sinha, R.A., Farah, B.L., Singh, B.K., Siddique, M.M., Li, Y., Wu, Y., Ilkayeva, O.R., Gooding, J., Ching, J., Zhou, J., Martinez, L., Xie, S., Bay, B.H., Summers, S.A., Newgard, C.B. and Yen, P.M. (2013) Caffeine Stimulates Hepatic Lipid Metabolism via Autophagy-Lysosomal Pathway. Hepatology, 59, 1366-1380.</mixed-citation></ref><ref id="hanspub.28655-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Liu, K., Lou, J., Wen, T., Yin, J., Xu, B., Ding, W., Wang, A., Liu, D., Zhang, C., Chen, D. and Li, N. (2013) Depending on the Stage of Hepatosteatosis, p53 Causes Apoptosis Primarily through Either DRAM-Induced Autophagy or BAX. Liver International, 33, 1566-1574. &lt;br&gt;https://doi.org/10.1111/liv.12238</mixed-citation></ref><ref id="hanspub.28655-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, J., Guo, R., Fung, M.L., Liong, E.C., Chang, R.C., Ching, Y.P. and Tipoe, G.L. (2013) Garlic-Derived S-Allylmercaptocysteine Ameliorates Nonalcoholic Fatty Liver Disease in a Rat Model through Inhibition of Apoptosis and Enhancing Autophagy. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 642920.  
&lt;br&gt;https://doi.org/10.1155/2013/642920</mixed-citation></ref><ref id="hanspub.28655-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Vescovo, T., Romagnoli, A., Perdomo, A.B., Corazzari, M., Ciccosanti, F., Alonzi, T., Nardacci, R., Ippolito, G., Tripodi, M., Garcia-Monzon, C., Lo Iacono, O., Piacentini, M. and Fimia, G.M. (2012) Autophagy Protects Cells from HCV-Induced Defects in Lipid Metabolism. Gastroenterology, 142, 644-653.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2011.11.033</mixed-citation></ref><ref id="hanspub.28655-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Werling, K. (2011) Role of Autophagy in the Pathogenesis of Liver Diseases. Orvosi Hetilap, 152, 1955-1961.  
&lt;br&gt;https://doi.org/10.1556/OH.2011.29269</mixed-citation></ref><ref id="hanspub.28655-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Qian, H.R., Yang, Y. and Wang, X.F. (2007) Curcumin Enhanced Adriamycin-Induced Human Liver-Derived Hepatoma G2 Cell Death through Activation of Mitochondria-Mediated Apoptosis and Autophagy. European Journal of Pharmaceutical Sciences, 43, 125-131. &lt;br&gt;https://doi.org/10.1016/j.ejps.2011.04.002</mixed-citation></ref><ref id="hanspub.28655-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Shinojima, N., Yokoyama, T., Kondo, Y., et al. (2007) Roles of the Akt/mTOR/p 70S6K and ERK1/2 Signaling Pathways in Curcumin-Induced Auto-Phagy. Autophagy, 3, 635-637. &lt;br&gt;https://doi.org/10.4161/auto.4916</mixed-citation></ref><ref id="hanspub.28655-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Aoki, H., Takada, Y., Kondo, S., Sawaya, R., Aggarwal, B.B. and Kondo, Y. (2007) Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways. Molecular Pharmacology, 72, 29-39.  
&lt;br&gt;https://doi.org/10.1124/mol.106.033167</mixed-citation></ref><ref id="hanspub.28655-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Jia, Y.L., Li, J., Qin, Z.H., et al. (2009) Autophagic and Apoptotic Mechanisms of Curcumin-Induced Death in K562 Cells. Journal of Asian Natural Products Research, 11, 918-928. &lt;br&gt;https://doi.org/10.1080/10286020903264077</mixed-citation></ref><ref id="hanspub.28655-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Shu, J.C., Zhao, J.R., Yang, D.H., et al. (2004) Effect of Curcumin on Proliferation and Apoptosis of Hepatic Stellate Cell Line. Chinese Journal of Digestion, 24, 282-284.</mixed-citation></ref><ref id="hanspub.28655-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Kang, H.C., Nan, J.X., Park, P.H., et al. (2002) Curcumin Inhibits Collagen Synthesis and Hepatic Stellate Cell Activation In-Vivo and In-Vitro. Journal of Pharmacy and Pharmacology, 54, 119-126.  
&lt;br&gt;https://doi.org/10.1211/0022357021771823</mixed-citation></ref><ref id="hanspub.28655-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, S. and Chen, A. (2004) Activation of PPAR Gamma Is Required for Curcumin to Induce Apoptosis and to Inhibit the Expression of Extracellular Matrix Genes in Hepatic Stellate Cells in Vitro. Biochemical Journal, 384, 149-157.</mixed-citation></ref><ref id="hanspub.28655-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, S. and Chen, A. (2007) Disruption of Transforming Growth Factor-Beta Signaling by Curcumin Induces Gene Expression of Peroxisome Proliferator-Activated Receptor-Gamma in Rat Hepatic Stellate Cells. American Journal of Physiology-Gastrointestinal and Liver Physiology, 292, 113-123. &lt;br&gt;https://doi.org/10.1152/ajpgi.00200.2006</mixed-citation></ref><ref id="hanspub.28655-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Lin, J. and Chen, A. (2011) Curcumin Diminishes the Impacts of Hyperglycemia on the Activation of Hepatic Stellate Cells by Suppressing Membrane Translocation and Gene Expression of Glucose Transporter-2. Molecular and Cellular Endocrinology, 333, 160-171. &lt;br&gt;https://doi.org/10.1016/j.mce.2010.12.028</mixed-citation></ref><ref id="hanspub.28655-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Tang, Y. and Chen, A. (2010) Curcumin Prevents Leptin Raising Glucose Levels in Hepatic Stellate Cells by Blocking Translocation of Glucose Transporter-4 and Increasing Glucokinase. British Journal of Pharmacology, 161, 1137-1149.  
&lt;br&gt;https://doi.org/10.1111/j.1476-5381.2010.00956.x</mixed-citation></ref><ref id="hanspub.28655-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Kinger, M., Kumar, S. and Kumar, V. (2017) Some Important Dietary Polyphenolic Compounds: An Anti-Inflammatory and Immunoregulatory Perspective. Mini-Reviews in Medicinal Chemistry, 17, 1-5.</mixed-citation></ref></ref-list></back></article>